
Eric J. Mccullough
Examiner (ID: 10645, Phone: (571)272-8885 , Office: P/1773 )
| Most Active Art Unit | 1773 |
| Art Unit(s) | 1773, 1797 |
| Total Applications | 445 |
| Issued Applications | 114 |
| Pending Applications | 85 |
| Abandoned Applications | 269 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 19202754
[patent_doc_number] => 20240174653
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-05-30
[patent_title] => SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS
[patent_app_type] => utility
[patent_app_number] => 18/386267
[patent_app_country] => US
[patent_app_date] => 2023-11-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 19243
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -10
[patent_words_short_claim] => 194
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18386267
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/386267 | SOLUBLE GUANYLATE CYCLATE ACTIVATORS FOR TREATING SYSTEMIC SCLEROSIS | Nov 1, 2023 | Pending |
| 18/287294 | ON DEMAND FEMALE CONTRACEPTIVE | Oct 17, 2023 | Pending |
Array
(
[id] => 20201514
[patent_doc_number] => 12404283
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-02
[patent_title] => c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 18/868756
[patent_app_country] => US
[patent_app_date] => 2023-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 83443
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18868756
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/868756 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | Jul 1, 2023 | Issued |
Array
(
[id] => 20201514
[patent_doc_number] => 12404283
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-09-02
[patent_title] => c-MYC mRNA translation modulators and uses thereof in the treatment of cancer
[patent_app_type] => utility
[patent_app_number] => 18/868756
[patent_app_country] => US
[patent_app_date] => 2023-07-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 3
[patent_figures_cnt] => 5
[patent_no_of_words] => 83443
[patent_no_of_claims] => 38
[patent_no_of_ind_claims] => 4
[patent_words_short_claim] => 134
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18868756
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/868756 | c-MYC mRNA translation modulators and uses thereof in the treatment of cancer | Jul 1, 2023 | Issued |
Array
(
[id] => 19018980
[patent_doc_number] => 20240075151
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-07
[patent_title] => CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS
[patent_app_type] => utility
[patent_app_number] => 18/202880
[patent_app_country] => US
[patent_app_date] => 2023-05-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35640
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18202880
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/202880 | CONJUGATES OF TUMOR NECROSIS FACTOR INHIBITORS TO FUNCTIONALIZED POLYMERS | May 25, 2023 | Pending |
Array
(
[id] => 19564726
[patent_doc_number] => 12139487
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-11-12
[patent_title] => Compounds and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/315526
[patent_app_country] => US
[patent_app_date] => 2023-05-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 14
[patent_figures_cnt] => 13
[patent_no_of_words] => 72394
[patent_no_of_claims] => 102
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18315526
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/315526 | Compounds and uses thereof | May 10, 2023 | Issued |
Array
(
[id] => 19065637
[patent_doc_number] => 20240100063
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS
[patent_app_type] => utility
[patent_app_number] => 18/303802
[patent_app_country] => US
[patent_app_date] => 2023-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41128
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18303802
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/303802 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | Apr 19, 2023 | Pending |
Array
(
[id] => 19793281
[patent_doc_number] => 12234210
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-02-25
[patent_title] => Synthesis of nirogacestat
[patent_app_type] => utility
[patent_app_number] => 18/304202
[patent_app_country] => US
[patent_app_date] => 2023-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9252
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 115
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18304202
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/304202 | Synthesis of nirogacestat | Apr 19, 2023 | Issued |
Array
(
[id] => 19065637
[patent_doc_number] => 20240100063
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS
[patent_app_type] => utility
[patent_app_number] => 18/303802
[patent_app_country] => US
[patent_app_date] => 2023-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41128
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18303802
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/303802 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | Apr 19, 2023 | Pending |
Array
(
[id] => 19065637
[patent_doc_number] => 20240100063
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-03-28
[patent_title] => COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS
[patent_app_type] => utility
[patent_app_number] => 18/303802
[patent_app_country] => US
[patent_app_date] => 2023-04-20
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41128
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => 0
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18303802
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/303802 | COMBINATION THERAPY OF PD-1 AXIS BINDING ANTAGONISTS AND LRRK2 INHITIBORS | Apr 19, 2023 | Pending |
Array
(
[id] => 19368288
[patent_doc_number] => 12060358
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-08-13
[patent_title] => Orally bioavailable, brain-penetrant compound with selectivity for the cannabinoid type 2 receptor with potential use towards visceral pain management and neurodegenerative disorders
[patent_app_type] => utility
[patent_app_number] => 18/191247
[patent_app_country] => US
[patent_app_date] => 2023-03-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 5
[patent_figures_cnt] => 8
[patent_no_of_words] => 27063
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 106
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18191247
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/191247 | Orally bioavailable, brain-penetrant compound with selectivity for the cannabinoid type 2 receptor with potential use towards visceral pain management and neurodegenerative disorders | Mar 27, 2023 | Issued |
Array
(
[id] => 19430899
[patent_doc_number] => 20240299397
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2024-09-12
[patent_title] => REHYDRATION COMPOSITION AND METHOD OF USE
[patent_app_type] => utility
[patent_app_number] => 18/119776
[patent_app_country] => US
[patent_app_date] => 2023-03-09
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11452
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18119776
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/119776 | Rehydration composition and method of use | Mar 8, 2023 | Issued |
Array
(
[id] => 18610769
[patent_doc_number] => 20230277499
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => FORMS OF ATICAPRANT
[patent_app_type] => utility
[patent_app_number] => 18/178961
[patent_app_country] => US
[patent_app_date] => 2023-03-06
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 33615
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -19
[patent_words_short_claim] => 31
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18178961
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/178961 | Forms of aticaprant | Mar 5, 2023 | Issued |
Array
(
[id] => 18595942
[patent_doc_number] => 20230270732
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-08-31
[patent_title] => BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION
[patent_app_type] => utility
[patent_app_number] => 18/115058
[patent_app_country] => US
[patent_app_date] => 2023-02-28
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9918
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 16
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18115058
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/115058 | BLOCKADE OF CHEMOKINE (C-C MOTIF) RECEPTOR 2 DURING FLUID RESUSCITATION | Feb 27, 2023 | Abandoned |
Array
(
[id] => 20262910
[patent_doc_number] => 12433878
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-07
[patent_title] => Uses of bupivacaine multivesicular liposomes as stellate ganglion block
[patent_app_type] => utility
[patent_app_number] => 18/171831
[patent_app_country] => US
[patent_app_date] => 2023-02-21
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 0
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 121
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18171831
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/171831 | Uses of bupivacaine multivesicular liposomes as stellate ganglion block | Feb 20, 2023 | Issued |
Array
(
[id] => 20270691
[patent_doc_number] => 12440455
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-10-14
[patent_title] => Methods of administering cannabinoids
[patent_app_type] => utility
[patent_app_number] => 18/169155
[patent_app_country] => US
[patent_app_date] => 2023-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 3164
[patent_no_of_claims] => 3
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 123
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18169155
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/169155 | Methods of administering cannabinoids | Feb 13, 2023 | Issued |
Array
(
[id] => 19457636
[patent_doc_number] => 12098116
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-24
[patent_title] => Crystalline prostacyclin (IP) receptor agonist and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/169016
[patent_app_country] => US
[patent_app_date] => 2023-02-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 35
[patent_figures_cnt] => 35
[patent_no_of_words] => 18606
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 53
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18169016
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/169016 | Crystalline prostacyclin (IP) receptor agonist and uses thereof | Feb 13, 2023 | Issued |
Array
(
[id] => 19975864
[patent_doc_number] => 12343320
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-01
[patent_title] => Intraveneous dofetilide to reduce the risk of developing AF/AFL post coronary bypass surgery
[patent_app_type] => utility
[patent_app_number] => 18/162092
[patent_app_country] => US
[patent_app_date] => 2023-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 1
[patent_figures_cnt] => 1
[patent_no_of_words] => 0
[patent_no_of_claims] => 23
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 231
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162092
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/162092 | Intraveneous dofetilide to reduce the risk of developing AF/AFL post coronary bypass surgery | Jan 30, 2023 | Issued |
Array
(
[id] => 19441171
[patent_doc_number] => 12091411
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-09-17
[patent_title] => IRAK degraders and uses thereof
[patent_app_type] => utility
[patent_app_number] => 18/162365
[patent_app_country] => US
[patent_app_date] => 2023-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 120670
[patent_no_of_claims] => 9
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 11
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162365
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/162365 | IRAK degraders and uses thereof | Jan 30, 2023 | Issued |
Array
(
[id] => 19675899
[patent_doc_number] => 12187749
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-01-07
[patent_title] => Application of dipyrrinato-iridium complexes in anti-tumor and anti-bacterial therapy
[patent_app_type] => utility
[patent_app_number] => 18/162205
[patent_app_country] => US
[patent_app_date] => 2023-01-31
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 17
[patent_figures_cnt] => 33
[patent_no_of_words] => 10875
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 59
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18162205
[rel_patent_id] =>[rel_patent_doc_number] =>) 18/162205 | Application of dipyrrinato-iridium complexes in anti-tumor and anti-bacterial therapy | Jan 30, 2023 | Issued |